Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Clinical trial NCT03522298 · COMPLETED
Trial details
- NCT number
- NCT03522298
- Sponsor
- Kazia Therapeutics Limited
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-05-15
- Primary completion
- 2023-03-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.